• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

CDKN2B-AS1: An indispensable long non-coding RNA in multiple diseases.
CONCLUSIONS: Long non-coding RNA CDKN2B-AS1 likely serves as a promising therapeutic target or prognosis biomarker in multiple human diseases. PMID: 32767927 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Design - August 4, 2020 Category: Drugs & Pharmacology Authors: Song C, Qi Y, Zhang J, Guo C, Yuan C Tags: Curr Pharm Des Source Type: research

New Analyses Suggest Favorable Results for STELARA ® (ustekinumab) When Used as a First-Line Therapy for Bio-Naïve Patients with Moderately to Severely Active Crohn’s Disease and Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 25, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from two new analyses of STELARA® (ustekinumab) for the treatment of adults with moderately to severely active Crohn’s disease (CD) and ulcerative colitis (UC).1,2 In a modelled analysisa focused on treatment sequencing using data from randomized controlled trials, network meta-analysis and literature, results showed patient time spent in clinical remission or response was highest when STELARA was used as a first-line advanced therapy for bio-naïve patients with moderately to severely acti...
Source: Johnson and Johnson - October 25, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Functional aging trajectories of older cancer survivors: a latent growth analysis of the US Health and Retirement Study
ConclusionOlder cancer survivors experience heterogeneous trajectories of functional aging that are largely characterized by comorbidities prior to diagnosis.Implication for Cancer SurvivorsResults can help identify older cancer survivors at increased risk for accelerated functional decline.
Source: Journal of Cancer Survivorship - February 26, 2022 Category: Cancer & Oncology Source Type: research

Oculoplastic Surgeries in Patients Older than 90 Years of Age
CONCLUSION: In our experience, oculoplastic surgeries among the elderly population are safe without significant complications and can usually be performed under local anesthesia. Advanced age should not prevent surgery, especially if the procedure may improve vision and quality of life.PMID:35377245 | DOI:10.1177/11206721221086153
Source: European Journal of Ophthalmology - April 4, 2022 Category: Opthalmology Authors: Muhammad Abumanhal Ilan Feldman Igal Leibovitch Ran Ben Cnaan Source Type: research

New insights into the comorbid conditions of Turner syndrome: results from a long-term monocentric cohort study
ConclusionsThis cohort study confirms the need for continuous, structured and multidisciplinary lifelong monitoring of TS, thus ensuring the early diagnosis of important comorbid conditions, including cancer, and their appropriate and timely treatment. In addition, these data highlight the need for the increased surveillance of specific types of cancer in TS, including thyroid carcinoma.
Source: Journal of Endocrinological Investigation - July 30, 2022 Category: Endocrinology Source Type: research

Janssen Data at ASCO GU Support Ambition to Transform Treatment of Prostate and Bladder Cancer Through Precision Medicine and Early Intervention
RARITAN, N.J., February 13, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced plans to present more than 20 abstracts featuring seven oncology therapies from its robust portfolio and pipeline at the annual American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium, taking place in San Francisco on February 16-18. Building on more than a decade of leadership in the development of medicines for people diagnosed with GU cancers, Janssen will present data demonstrating its ambition to advance patient-centered treatment through precision medicine, real-world evidence a...
Source: Johnson and Johnson - February 13, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news

Association between baseline cardiovascular risk and incidence rates of major adverse cardiovascular events and malignancies in patients with psoriatic arthritis and psoriasis receiving tofacitinib
CONCLUSION: In tofacitinib-treated patients with PsA/PsO, increased ASCVD risk and baseline MetS were associated with higher IRs for MACE and malignancies. Our results support assessing CV risk in patients with PsA/PsO and suggest enhanced cancer monitoring in those with increased ASCVD risk.REGISTRATION CLINICALTRIALSGOV: NCT01877668/NCT01882439/NCT01976364/NCT00678210/NCT01710046/NCT01241591/NCT01186744/NCT01276639/NCT01309737/NCT01163253.PLAIN LANGUAGE SUMMARY: People who have psoriatic arthritis or psoriasis may have more heart-related problems and cancer if they have a higher risk of cardiovascular disease: A study in...
Source: Adv Data - February 13, 2023 Category: Epidemiology Authors: Lars E Kristensen Bruce Strober Denis Poddubnyy Ying-Ying Leung Hyejin Jo Kenneth Kwok Ivana Vranic Dona L Fleishaker Lara Fallon Arne Yndestad Dafna D Gladman Source Type: research

Pages: 1  2